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Objective. We report intraoral granulomatous foreign body reactions in patients treated with calcium hydroxylapatite (CHA)
or poly-L-lactic acid (PLA).
Study Design. Clinical and histopathologic data were obtained from 25 patients who developed orofacial nodules or swelling
after dermal filler injections.
Results. All 25 patients were women aged 35 to78 years (median, 55 years). All had a history of injection of CHA (n ¼ 13) or
PLA (n ¼ 12) to the lips, nasolabial area, or mental area. Two patients developed cutaneous nodules at the sites of injections; all
others presented with intraoral nodules (labial/buccal or vestibular mucosa) distant from the site of injections, suggestive of filler
migration. Five of 21 cases presented with pain. Histopathologically, CHA presented as a diffuse mass of mauve-gray or beige,
nonrefractile spherules, and PLA as rice- or spindle-shaped, geometric, refractile bodies within circumscribed nodules.
Conclusions. Cutaneous injections of CHA and PLA fillers may induce granulomatous reactions presenting as intraoral
nodules distant from the injection sites. (Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:105-110)In the 1980s, bovine collagen was introduced to treat
wrinkles and soft tissue defects, and since that time,
many injectable materials have been developed in
cosmetic dermatology to smooth wrinkles, treat facial
fat atrophy, and provide soft tissue augmentation.1 In
the orofacial region, perioral tissues such as the lips,
nasolabial fold, periocular areas, and cheek areas are
common sites for dermal ﬁller injection.2
Cosmetic dermal ﬁllers may be classiﬁed into degrad-
able/resorbable ﬁllers (such as collagen and hyaluronic
acid) or permanent/nonresorbable ﬁllers (such as sili-
cone).3 Dermal ﬁllers may also be categorized into ﬁlling/
volumizing, biostimulatory, or combined ﬁllers based on
their space-ﬁlling or stimulatory effects on the dermal
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volumizer ﬁllers, and calcium hydroxylapatite (CHA) and
poly-L-lactic acid (PLA) have both volumizing and bio-
stimulatory properties.5
The present study reports the histopathologic and
clinical features of 25 cases of foreign body granulo-
matous reactions to CHA or PLA, most of which
occurred within the oral cavity.
MATERIALS AND METHODS
All cases were accessioned at StrataDx, Lexington,
MA, USA, from January 2010 through May 2013. Each
patient’s age, gender, lesion site, and lesion size were
recorded along with her clinical signs and symptoms.
Data regarding the ﬁller injections were obtained from
the submitting dentist or from the patient (with per-
mission from the dentist to contact her directly). The
histopathologic features were recorded.
RESULTS
Clinical findings
Clinical characteristics of the patients are shown
in Table I. All 25 patients were women aged 35 toStatement of Clinical Relevance
Cutaneous cosmetic ﬁller injections may induce
granulomatous foreign body reactions with distinct
and readily recognized histopathologic features. Such
ﬁllers may migrate from the original injection sites,
resulting in nodules that may mimic soft tissue tumors.
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Table I. Clinical features of the cases
Type of
injected
ﬁller
Case
report
No.
Gender/
age (y) Site of lesion/size (cm) Site of injection
Clinical symptoms
and signs
Months between
ﬁller injection
and ﬁrst notice
CHA 1 F/67 Right upper labial mucosa/1.4 Right upper lip Painful swelling 6
2 F/46 Upper labial mucosa/1.2-1.5 Upper lip Painless swelling 6
3 F/68 Lower labial mucosa/1.0 Lower lip Painful swelling 5
4 F/53 Skin, left chin/2.0 Skin, left chin Unknown Unknown
5 F/59 Left nasolabial fold/1.6 Left nasolabial fold Painful ﬁrm swelling 8
6 F/71 Right upper labial mucosa/1.5 Right nasolabial fold Painless nodules 10
7 F/48 Mandibular vestibular area/0.5 Labial-mental fold Painless yellow-white nodule 2
8 F/71 Upper lip/1.0 Right nasolabial fold Painless nodule 12
9 F/54 Right mandibular vestibule,
canine area/0.6
Submental fold (last one
of multiple injections)
Painless, mobile ﬁrm yellow
nodule
3
10 F/51 Left anterior mandibular
vestibule/0.6
Skin, near the commissure Painless, yellow mass 6
11 F/57 Lower vestibule/0.5 Bilaterally midway between
lips and chin
Painless ﬁrm mass 5
12 F/35 Right lower lip/1.0 Unknown Firm nodule Unknown
13 F/55 Right lower lip/0.7 Unknown Yellowish ﬁrm mass Unknown
PLA 14 F/69 Right posterior maxillary
vestibule/0.6
Right nasolabial fold Painful ﬁrm nodule 24-36
15 F/54 Right buccal mucosa/1.0 Right nasolabial fold Painful ﬁrm nodule 6
16 F/62 Right labial and buccal
mucosa/3.0
Bilateral nasolabial folds Painless swelling 14
17 F/51 Right buccal mucosa/1.5 Right nasolabial fold Painless nodule 6
18 F/78 Left maxillary vestibule,
premolar area/0.7
Left nasolabial fold Painless, ﬁrm, mobile mass 9
19 F/48 Mandibular vestibule/0.6 Lower lip Painless ﬁrm yellow nodule 9
20 F/54 Left buccal vestibule/1.3 Left mental area, near border
of the mandible
Painless ﬁrm nodule 6-8
21 F/56 Left maxillary vestibule/0.8 Lip Painless, 2 ﬁrm yellow
movable masses
7
22 F/60 Left maxillary vestibule,
lateral incisor area/1.5
Nasolabial fold (multiple
injections)
Painless ﬁrm nodule Unknown
23 F/44 Left mandibular vestibule,
premolar area/0.3
Nasolabial fold Painless ﬁrm yellow nodule 12
24 F/40 Right mandibular alveolar
mucosa, premolar area/0.5
Nasolabial fold Painless ﬁrm nodule 5
25 F/66 Left maxillary vestibule,
canine area/0.6
Unknown Firm, multilobulated mass Unknown
CHA, calcium hydroxylapatite; F, female; PLA, poly-L-lactic acid.
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received their injections extraorally, and 23 presen-
ted with intraoral nodules (lip mucosa, maxillary or
mandibular vestibular areas, or buccal mucosa).
Nodules of the skin developed within the nasolabial
fold or chin in 2 patients. In the 20 patients with
known dates of injections, the time elapsed from
injection to initial detection of the lesion ranged from
2 to 36 months, with a median of 6.5 months. Seven
cases were described by their surgeons as yellow/
yellowish nodules (Figure 1). Five of 21 patients re-
ported pain.
Thirteen patients received injections of CHA (Radi-
esse; Bioform Medical, San Mateo, CA, USA) and
subsequently presented with a nodule, swelling, or
plaque within 2 to 12 months (median, 6 months). As
noted in Table I, in 6 patients (cases 1 to 6), the nodulesdeveloped in the labial mucosa, skin of the chin, or
nasolabial fold, which were in the vicinity of the initial
sites of injection. However, in 5 patients (cases 7 to 11),
the nodules developed away from the injection sites
(the skin of the nasolabial fold, commissure, or mental
region).
Twelve patients reported a history of PLA (Sculptra,
Dermik, Berwyn, PA, USA) injection with subsequent
development of nodules and plaques 5 to 36 months
(median, 8 months) after injection. All patients pre-
sented with nodules in the maxillary or mandibular
vestibular areas or the labial or buccal mucosa,
whereas the sites of injection were the skin of the
nasolabial fold, lip, or mental region (see Table I). In
2 cases (cases 23 and 24), the ﬁller migrated from
the nasolabial fold injection site to the mandibular
vestibule.
Fig. 1. Yellow plaque of the lower lip associated with
calcium hydroxylapatite injection.
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Each of the cases with CHA injection showed a nonen-
capsulated mass of regularly sized mauve-to-gray or
beige spherules, each measuring 20 to 40 mm, sur-
rounded by a histiocytic and giant cell granulomatous
foreign body reaction (Figure 2, A). These spherules
were not refractile in polarized light and were noted
between muscle ﬁbers and within the cytoplasm of giant
cells (see Figure 2, B, C). In 11 of 13 cases (85%), there
were minimal to moderate chronic inﬂammation and
ﬁbrosis (see Figure 2, D). In 11 of 13 biopsies, CHA was
present between skeletal muscle ﬁbers, and myositis was
evident in 1 case. Lobules of salivary gland were present
in 2 cases, with 1 case exhibiting mild to moderate
chronic sialadenitis, although foreign material was not
noted within the salivary gland parenchyma.
Each of the cases injected with PLA showed well-
circumscribed lobules consisting of ovoid, rice-shaped,
or spindle-shaped refractile structures, often within
the cytoplasm of giant cells, surrounded by a non-
necrotizing granulomatous reaction (Figure 3, A, B, C).
The length and width of these structures varied from 50
to 150 mm and from 15 to 35 mm, respectively. A
minimal to moderate chronic inﬂammatory inﬁltrate
and ﬁbrosis were evident in all cases (see Figure 3, D).
Two cases showed necrosis (see Figure 3, E), and 2
cases had scattered eosinophils. Pseudomicrocyst
formation (7 cases) and asteroid bodies (5 cases) were
evident (see Figure 3, A and F). Skeletal muscle ﬁbers
were present in 5 cases that showed PLA particles in
between ﬁbers, and myositis was noted in 2 cases.
Chronic sialadenitis was seen in 2 of 4 biopsies, which
contained lobules of salivary gland tissue, but these did
not contain ﬁller material.
A silicone granuloma reviewed for comparison had
a diffuse, nonencapsulated mass of macrophages with
vacuolated cytoplasm. The intracytoplasmic vacuolesvaried in size, and some cells contained numerous small
vacuoles, exhibiting a “bubbly” or vesicular appearance
(Figure 4, A). The immunohistochemical study for
CD163 conﬁrmed the presence of histiocytes (see
Figure 4, B), whereas the study for S-100 protein was
negative, conﬁrming that the cells were not adipocytic.
There was minimal to no nuclear atypia.
DISCUSSION
The use of cosmetic dermal ﬁllers has been on the
rise during the past few decades.6 Ideally, injectable
cosmetic dermal substances should be biocompatible,
safe, and stable at the injection site with no migration
potential, and they should induce minimal foreign body
reaction.3 Although dermal ﬁllers are generally nonan-
tigenic and nonirritating, acute short-term injection
site events, such as discomfort, erythema, bruising,
swelling, pain, pruritus, or hematoma formation, may
occur.6 More serious complications, such as allergic
hypersensitivity reactions, vascular occlusion, necrosis,
scarring, or (in rare cases) blindness, have been
reported.6-8
Granulomas may occur as intermediate- or late-term
adverse reactions occurring weeks or years after treat-
ment.8,9 In this study of CHA and PLA, most patients
noted persistent nodules 6 to 8 months (range, 2-36
months) after the injection. With regard to PLA, others
have also reported lesions developing at 6 months,2,10
although this is in contrast to the mean of 19 months
(range, 6-60 months) reported by Alijotas-Reig et al.11
The clinical incidence of foreign body granulomas
associated with cosmetic dermal ﬁllers is infrequent
and has been reported to range from 0.02% to 1%,
depending on the chemical nature of the dermal ﬁller,
its surface structure and properties, and the presence of
impurities.7,12 In this study, we reported 25 cases of
granulomatous foreign body reaction to CHA or PLA.
Interestingly, all but 2 (which presented on the skin of
the nasolabial fold and chin) presented as nodules on
the mucosal aspect of the lips or intraoral regions. We
also described in detail the histopathologic appearance
of these ﬁllers.
CHA is composed of microspheres suspended in an
aqueous gel carrier (glycerin and sodium carboxy-
methylcellulose).13 After injection, the aqueous carrier
is gradually absorbed over time, but the CHA micro-
spheres serve as a matrix for the production of new
collagen.7,13,14 Lip nodules caused by CHA occur in
7.0% to 12.4% of cases, with early to immediate-stage
nodules resolving with massage and later-stage ones
being managed with intralesional steroid injections or
excision.15,16 Daley et al.17 reported similar foreign
body granulomas in 8 cases on the lips or mandibular
labial vestibule, and Eversole et al.18 reported an
additional 3 cases. In our report, 2 patients presented
Fig. 2. A, Calcium hydroxylapatite within the lamina propria (hematoxylin-eosin, original magniﬁcation 100). B, Fragmentation
of skeletal muscle tissue by calcium hydroxylapatite and foreign body reaction (hematoxylin-eosin, original magniﬁcation 100).
C, Regularly sized mauve-to-gray or beige spherules of calcium hydroxylapatite surrounded by histiocytes and within foreign body
giant cells (hematoxylin-eosin, original magniﬁcation 400). D, Calcium hydroxylapatite and associated lymphocytic inﬁltrate
(hematoxylin-eosin, original magniﬁcation 200).
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into the nasolabial folds. Nodules developed in the
vestibular areas in another 4 cases, in which there was
a history of injection in the skin of the nasolabial,
labial-mental, or submental fold areas.
PLA is a synthetic peptide polymer of the a-hydroxy-
acid family that is commonly used in resorbable sutures.
It is suspended in mannitol and carboxymethylcellulose.
As with CHA, the carrier is rapidly absorbed, and the
PLA acts as a stimulant for new collagen produc-
tion.7,15,19 Although injectable PLA is considered
a biocompatible dermal ﬁller, nodules and foreign body
granulomas have also been described.2,10,18-23 Valantin
et al.24 reported palpable but invisible nodules in 44% of
HIV-infected patients who received facial PLA injec-
tions, although most of these resolved. In a study by
Vleggaar,25 approximately 3.2% of over 2131 patients
reported the presence of invisible subcutaneous papules,
and approximately 30% of these resolved; however,
1.2% reported visible subcutaneous papules, and 0.1% of
the whole group had histologic conﬁrmation of granu-
lomas. Saylan26 reported that granulomas developed in
12% of cases, but no histopathologic evidence was
shown. In the current study, all PLA cases presented as
intraoral nodules, and 11 of those had known sites of
injection in the skin.
With only 2 exceptions, the injected CHA and PLA
in this study presented as nodules on the mucosal aspectof the lips or intraoral regions, including the vestibular
region or buccal mucosa. The “migration” of ﬁllers
may be explained by high-volume and high-pressure
injection, or it may be caused by muscle movement or
gravity.27 Such mechanisms may result in the occurrence
of nodules within the vestibule, deep to the cutaneous
sites where the original injection had occurred, or on the
labial mucosa when the injection had occurred in the
overlying skin. Laeschke27 suggests the term “disloca-
tion” rather than “migration” for this phenomenon.
Migration of dermal ﬁller has been documented previ-
ously in the literature.17,22,28 It is possible that some
patients have an innate susceptibility to migration of
dermal ﬁller because of differences in the embryologic
fusion plane.22 Cosmetic dermal ﬁllers are widely used,
and migration into intraoral locations may raise the
suspicion of a mucocele, salivary gland tumor, or soft
tissue tumor.
Although all cases showed collections of epithelioid
histiocytes with engulfed foreign material, each of the 2
ﬁllers has a distinct morphology.7 The regularly sized
mauve-to-gray or beige spherules of CHA measured 20
to 40 mm, whereas the ovoid, rice-shaped, or spindle-
shaped refractile structures of PLA measured 50 to
150 mm in length and 15 to 35 mm in width. The
granulomas associated with PLA may contain asteroid
bodies, as noted here and in previous reports.2,20 The
histopathologic features of these 2 dermal ﬁllers are
Fig. 3. A, Well-circumscribed nodules of poly-L-lactic acid within the lamina propria with pseudomicrocystic space (hematoxylin-
eosin, original magniﬁcation 100). B, Non-necrotizing granulomas with ovoid, rice-shaped, or spindle-shaped poly-L-lactic acid
structures within giant cells (hematoxylin-eosin, original magniﬁcation 200). C, Rice- and spindle-shaped poly-L-lactic
acid structures refractile in polarized light (polarized light, hematoxylin-eosin, original magniﬁcation 200). D, Poly-L-lactic acid
granuloma with associated ﬁbrosis (hematoxylin-eosin, original magniﬁcation 100). E, Poly-L-lactic acid granuloma with
associated chronic inﬂammation and necrosis (hematoxylin-eosin, original magniﬁcation 100). F, Poly-L-lactic acid granuloma
with asteroid bodies (hematoxylin-eosin, original magniﬁcation 400).
Fig. 4. A, Silicone granuloma with vacuolated and “bubbly” histiocytes with variably sized intracytoplasmic vacuoles and signet
ringelike cells (hematoxylin-eosin, original magniﬁcation 400). B, Silicone granuloma with vacuolated histiocytes positive for
CD163 (immunohistochemistry CD163, original magniﬁcation 200).
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characterized by lipid-like vacuoles within the histio-
cytes. Furthermore, the granulomas formed by CHA
were poorly circumscribed, whereas those of PLA were
generally well circumscribed.
Variable degrees of chronic inﬂammation and
ﬁbrosis were noted in a majority of cases. The reason
for such an inﬂammatory response to biocompatible
materials is still unclear, but the volume of injected
dermal ﬁllers, repeated injections using the micro-
droplet technique (repeated injections over a larger
surface may stimulate more macrophage activity thansingle injections), impurities within a ﬁller, incorrect
depth of injection, or the large size of some particles
may play a role.10,12
In conclusion, CHA and PLA produce granuloma-
tous inﬂammation with distinct and readily recognized
features. Such ﬁllers may migrate from the original
injection site, resulting in painful or painless nodules
that may mimic soft tissue tumors.
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